Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 2, 2010, Pages 251-258

  Fujita, Ken Ichi ^a,b   Ando, Yuichi ^a   Yamamoto, Wataru ^a   Miya, Toshimichi ^a   Endo, Hisashi ^a   Sunakawa, Yu ^a   Araki, Kazuhiro ^a   Kodama, Keiji ^a   Nagashima, Fumio ^a,b   Ichikawa, Wataru ^a   Narabayashi, Masaru ^a   Akiyama, Yuko ^a,b   Kawara, Kaori ^a   Shiomi, Mari ^c   Ogata, Hiroyasu ^c   Iwasa, Hiroyasu ^b   Okazaki, Yasushi ^b   Hirose, Takashi ^a   Sasaki, Yasutsuna ^a,b  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Adverse reaction; Cancer patients; Morphine; Pharmacogenetics

Indexed keywords

GENOMIC DNA; GLUCURONOSYLTRANSFERASE 2B7; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MORPHINE SULFATE; MU 1 OPIATE RECEPTOR; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DROWSINESS; DRUG CLEARANCE; FATIGUE; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; JAPANESE; MALE; NAUSEA; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING;

ADULT; AGED; ANALGESICS, OPIOID; ASIAN CONTINENTAL ANCESTRY GROUP; DELAYED-ACTION PREPARATIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; JAPAN; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; P-GLYCOPROTEIN; PAIN; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU;

EID: 71349085144     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1029-2     Document Type: Article

References (34)

1. WE Evans MV Relling 1999 Pharmacogenomics: translating functional genomics into rational therapeutics Science 286 487 491 10.1126/science.286. 5439.487 1:CAS:528:DyaK1MXmvVOhtL0%3D 10521338
2. WE Evans HL McLeod 2003 Pharmacogenomics-drug disposition, drug targets, and side effects N Engl J Med 348 538 549 10.1056/NEJMra020526 1:CAS:528:DC%2BD3sXovVKlsQ%3D%3D 12571262 (Pubitemid 36159890)
3. WE Evans MV Relling 2004 Moving towards individualized medicine with pharmacogenomics Nature 429 464 468 10.1038/nature02626 1:CAS:528: DC%2BD2cXkt1Onsbo%3D 15164072 (Pubitemid 38715141)
4. RS Huang MJ Ratain 2009 Pharmacogenetics and pharmacogenomics of anticancer agents CA Cancer J Clin 59 42 55 10.3322/caac.20002 19147868
5. BL Coffman GR Rios CD King, et al. 1997 Human UGT2B7 catalyzes morphine glucuronidation Drug Metab Dispos 25 1 4 1:CAS:528:DyaK2sXmtlygug%3D%3D 9010622
6. LL Christrup 1997 Morphine metabolites Acta Anaesthesiol Scand 41 116 122 10.1111/j.1399-6576.1997.tb04625.x 1:CAS:528:DyaK2sXhs1OmsrY%3D 9061094
7. T Hirota I Ieiri H Takane, et al. 2003 Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy Drug Metab Dispos 31 677 680 10.1124/dmd.31.5.677 1:CAS:528:DC%2BD3sXjt1GgtLg%3D 12695358 (Pubitemid 36444178)
8. Y Duguay C Báár F Skorpen, et al. 2004 A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity Clin Pharmacol Ther 75 223 233 10.1016/j.clpt.2003.10.006 1:CAS:528:DC%2BD2cXhslenurc%3D 15001974 (Pubitemid 38314872)
9. AA Somogyi DT Barratt JK Coller 2007 Pharmacogenetics of opioids Clin Pharmacol Ther 81 429 444 10.1038/sj.clpt.6100095 1:CAS:528:DC%2BD2sXktl2lurk%3D 17339873 (Pubitemid 46364493)
10. C Wandel R Kim M Wood, et al. 2002 Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein Anesthesiology 96 913 920 10.1097/00000542-200204000-00019 1:CAS:528:DC%2BD38XjtFOlu78%3D 11964599 (Pubitemid 34266685)
11. K Sai M Itoda Y Saito, et al. 2006 Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differences Ann Hum Genet 70 605 622 10.1111/j.1469-1809.2006.00260.x 1:CAS:528: DC%2BD28XpvFOmtrw%3D 16907707 (Pubitemid 44173372)
12. D Campa A Gioia A Tomei, et al. 2008 Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief Clin Pharmacol Ther 83 559 566 10.1038/sj.clpt.6100385 1:CAS:528:DC%2BD1cXjsFClu7s%3D 17898703
13. KS LaForge V Yuferov MJ Kreek 2000 Opioid receptor and peptide gene polymorphisms: potential implications for addictions Eur J Pharmacol 410 249 268 10.1016/S0014-2999(00)00819-0 1:CAS:528:DC%2BD3cXovFKjurY%3D 11134674 (Pubitemid 32008148)
14. MR Hoehe K Köpke B Wendel 2000 Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence Hum Mol Genet 9 2895 2908 10.1093/hmg/9.19.2895 1:CAS:528:DC%2BD3cXoslWmsLc%3D 11092766
15. Y Zhang D Wang AD Johnson, et al. 2005 Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G J Biol Chem 280 32618 32624 10.1074/jbc.M504942200 1:CAS:528:DC%2BD2MXhtVWiur7I 16046395 (Pubitemid 41368304)
16. P Klepstad TT Rakvåg S Kaasa, et al. 2004 The 118A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease Acta Anaesthesiol Scand 48 1232 1239 10.1111/j.1399-6576.2004.00517.x 1:CAS:528: DC%2BD2cXhtVOqtL%2FN 15504181 (Pubitemid 39490855)
17. K Sai N Kaniwa M Itoda, et al. 2003 Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan Pharmacogenetics 13 741 757 10.1097/00008571-200312000-00005 1:CAS:528:DC%2BD3sXptlelsbo%3D 14646693 (Pubitemid 38429252)
18. BL Coffman CD King GR Rios, et al. 1998 The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268) Drug Metab Dispos 26 73 77 1:CAS:528:DyaK1cXos1entQ%3D%3D 9443856
19. I Meineke S Freudenthaler U Hofmann, et al. 2002 Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine Br J Clin Pharmacol 54 592 603 10.1046/j.1365-2125.2002. t01-1-01689.x 1:CAS:528:DC%2BD3sXnvVaguw%3D%3D 12492606 (Pubitemid 36002586)
20. RB Kim BF Leake EF Choo, et al. 2001 Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 189 199 10.1067/mcp.2001.117412 1:CAS:528:DC%2BD3MXmslygs7o%3D 11503014 (Pubitemid 32777772)
21. S Hoffmeyer O Burk O von Richter, et al. 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 3473 3478 10.1073/pnas.050585397 1:CAS:528: DC%2BD3cXitlWqtL8%3D 10716719 (Pubitemid 30183327)
22. J Fellay C Marzolini ER Meaden, et al. 2002 Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study Lancet 359 30 36 10.1016/S0140-6736(02)07276-8 1:CAS:528:DC%2BD38XmsV2mtw%3D%3D 11809184 (Pubitemid 34119193)
23. M Nasi V Borghi M Pinti, et al. 2003 MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients AIDS 17 1696 1698 10.1097/00002030-200307250-00016 12853754 (Pubitemid 36951692)
24. A Saitoh KK Singh CA Powell, et al. 2005 An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children AIDS 19 371 380 10.1097/01.aids.0000161766. 13782.2f 1:CAS:528:DC%2BD2MXitVeitbw%3D 15750390
25. C Verstuyft F Marcellin L Morand-Joubert, et al. 2005 Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy AIDS 19 2127 2131 10.1097/01.aids.0000196122.91633.04 1:CAS:528:DC%2BD2MXht1Sgt7fI 16284462
26. DW Haas LM Smeaton RW Shafer, et al. 2005 Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study J Infect Dis 192 1931 1942 10.1086/497610 1:CAS:528:DC%2BD2MXhtlSrtLrM 16267764 (Pubitemid 41681891)
27. K Kajinami ME Brousseau JM Ordovas, et al. 2004 Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner Am J Cardiol 93 1046 1050 10.1016/j.amjcard.2004.01.014 1:CAS:528:DC%2BD2cXjtVems7w%3D 15081455 (Pubitemid 38479466)
28. A Siddiqui R Kerb ME Weale, et al. 2003 Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 N Engl J Med 348 1442 1448 10.1056/NEJMoa021986 1:CAS:528:DC%2BD3sXivVCgs7g%3D 12686700 (Pubitemid 36407173)
29. HX Zheng SA Webber A Zeevi, et al. 2004 The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis Pediatr Transplant 8 551 557 10.1111/j.1399-3046. 2004.00223.x 1:CAS:528:DC%2BD2MXhtFWrsr4%3D 15598322 (Pubitemid 40052351)
30. SY Yi KS Hong HS Lim, et al. 2004 A variant 2677A allele of the MDR1 gene affects fexofenadine disposition Clin Pharmacol Ther 76 418 427 10.1016/j.clpt.2004.08.002 1:CAS:528:DC%2BD2cXpslWnt7Y%3D 15536457 (Pubitemid 39469866)
31. N Morita T Yasumori K Nakayama 2003 Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities Biochem Pharmacol 65 1843 1852 1:CAS:528:DC%2BD3sXktVOrsL0%3D 12781336
32. C Kimchi-Sarfaty JJ Gribar MM Gottesman 2002 Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system Mol Pharmacol 62 1 6 10.1124/mol.62.1.1 1:CAS:528:DC%2BD38Xlt1KqtLw%3D 12065748 (Pubitemid 34680509)
33. L Coulbault M Beaussier C Verstuyft, et al. 2006 Environmental and genetic factors associated with morphine response in the postoperative period Clin Pharmacol Ther 79 316 324 10.1016/j.clpt.2006.01.007 1:CAS:528: DC%2BD28XjtFaiurw%3D 16580900
34. CC Reyes-Gibby S Shete T Rakvåg, et al. 2007 Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene Pain 130 25 30 10.1016/j.pain.2006.10.023 1:CAS:528: DC%2BD2sXmtVKisrs%3D 17156920 (Pubitemid 46850782)